Astrid Murumägi is a Senior Researcher at the Kallioniemi group. She received her PhD in Molecular Immunology at the University of Tampere, where she studied the transcriptional regulation of autoimmune regulator AIRE with Prof. Pärt Peterson and Prof. Olli Silvennoinen. During her postdoctoral training she transitioned to systems biology and genomics by joining Prof. Olli Kallioniemi´s team at FIMM in 2009. Her work is focused on applying systems medicine in cancer research. She is involved in the FIMM Grand Challenge on Individualized Systems Medicine program. More specifically, she is responsible for the ovarian cancer and melanoma personalized medicine projects, where primary cancer models are used for comprehensive drug sensitivity testing and molecular profiling to identify best treatment strategies for cancer patients.
Karvonen H, Chiron D, Niininen W, Ek S, Jerkeman M, Moradi E, Nykter M, Heckman CA, Kallioniemi O, Murumägi A, Ungureanu D. Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma. Blood Advances. Oct 2017.
Mpindi JP, Yadav B, Östling P, Gautam P, Malani D, Murumägi A, Hirasawa A, Kangaspeska S, Wennerberg K, Kallioniemi O, Aittokallio T. Consistency in drug response profiling. Nature. 2016 Nov 30;540(7631):E5-E6.
Malani D, Murumägi A, Yadav B, Kontro M, Eldfors S, Kumar A, Karjalainen R, Majumder MM, Ojamies P, Pemovska T, Wennerberg K, Heckman C, Porkka K, Wolf M, Aittokallio T, Kallioniemi O. Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML. Leukemia. 2017 May;31(5):1187-1195.
Pemovska T, Kontro M, Yadav B, Edgren H, Eldfors S, Szwajda A, Almusa H, Bespalov MM, Ellonen P, Elonen E, Gjertsen BT, Karjalainen R, Kulesskiy E, Lagström S, Lehto A, Lepistö M, Lundán T, Majumder MM, Marti JML, Mattila P, Murumägi A, Mustjoki S, Palva A, Parsons A, Pirttinen T, Rämet ME, Suvela M, Turunen L, Västrik I, Wolf M, Knowles J, Aittokallio T, Heckman CA, Porkka K, Kallioniemi O, Wennerberg K. Individualized Systems Medicine (ISM) strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discovery 2013; 3:1416-1429.
Edgren H, * Murumägi A, * Kangaspeska S, * Nicorici D, Hongisto V, Kleivi K, Rye IH, Nyberg S, Wolf M, Borresen-Dale A-L, Kallioniemi O. Identification of fusion genes in breast cancer by paired-end-sequencing. Identification of fusion genes in breast cancer by paired-end-sequencing. Genome Biology 2011. 19;12(1):R6. * equal contribution.